Indications
Platelet aggregation inhibition as adjunct to percutaneous
transluminal coronary angioplasty or atherectomy (PTCA).
Description
Abciximab (c7E3) is a chimeric mouse-human monoclonal antibody
directed against the GP IIb/IIIa receptor; its mechanism of action
is thought to be steric hindrance of the receptor itself as
opposed to direct binding to the RGD binding site of the receptor.
It also inhibits the vitronectin (av b3)receptor, which mediates
both platelet coagulation as well as endothelial and vascular
smooth muscle cell proliferation.
Dosage
0.25 mg/kg administered 10-60 minutes before the start of PTCA `
followed by a continuous I.V.. Injection of 10 mcg/min. for 12
hours.
Presentations
Vial 5ml
Note :This product
information is intended only for residents of the India.
Taj Pharmaceuticals Limited, medicines help to treat and prevent
a range of conditions—from the most common to the most
challenging—for people around the world.
Information for Health Care Professionals
*** Please consult local Prescribing
Information for any product before use. This website is an
international information resource for healthcare professionals
with an interest in disease management. This website is not
intended to replace the advice of a qualified healthcare
professional. Above brand is a trademark of the Taj group of
companies (Taj Pharmaceuticals Limited)
Quality
